Incidence of cutaneous malignancy following the concomitant use of ciclosporin and narrowband ultraviolet B phototherapy in patients with vitiligo

This nationwide population-based cohort study investigates the incidence of cutaneous malignancies associated with the concomitant treatment of ciclosporin and narrowband ultraviolet B (NBUVB) phototherapy in patients with vitiligo, using the Korean National Health Insurance Service database. Concomitant ciclosporin and NBUVB phototherapy may not significantly increase the incidence of cutaneous malignancies. Given the chronic autoimmune nature of vitiligo and its economic impact, these findings provide novel insights into the potential safety of these combination regimens.